NorthRock Partners’s Cyclerion Therapeutics CYCN Stock Holding History

NorthRock Partners’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-500	Closed	-$31K	–	238
2020 Q4	$31K	Buy	+500	New	+$34.1K	﹤0.01%	230

Other funds holding CYCN

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

NorthRock Partners's CYCN Position: Q1 2021 in Review

NorthRock Partners sold out of Cyclerion Therapeutics (CYCN) in Q1 2021, closing a stake of 500 shares — an estimated $31K sold.

NorthRock Partners first reported a position in CYCN in Q4 2020 and held it in 1 quarter. The position peaked at $31K in Q4 2020. 70 funds tracked by Wall St. Rank hold CYCN as of Q1 2021.

NorthRock Partners reported no remaining Cyclerion Therapeutics position as of Q1 2021 after selling out during the quarter.
NorthRock Partners sold 500 Cyclerion Therapeutics shares in Q1 2021, an estimated $31K.
NorthRock Partners first reported a position in Cyclerion Therapeutics in Q4 2020 and held it in 1 quarter.
NorthRock Partners's Cyclerion Therapeutics position peaked at $31K in Q4 2020.
70 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q1 2021.

Based on NorthRock Partners's 13F filing for Q1 2021, filed 11 May 2021.